Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-7117 Drug-Drug Interaction Study in Healthy Subjects
NCT04793295Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (4 cohorts), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to infinity and 1 more. Started Mar 2021; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT04793295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793295.